Opinion|Videos|June 5, 2025
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety.
Advertisement
Episodes in this series
The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).
- ABLE-32 Trial: This is a phase 3, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of nadofaragene firadenovec in patients with intermediate-risk NMIBC. The study aims to assess the treatment’s ability to reduce the recurrence and progression of bladder cancer in this patient population.
- ABLE-41 Trial: This is a real-world, observational trial that investigates the use of nadofaragene firadenovec outside the controlled environment of clinical trials. The study seeks to gather data on its effectiveness and safety in routine clinical practice, providing insights into its use across a broader, more diverse patient population.
Both trials contribute to expanding the understanding of nadofaragene firadenovec as a potential treatment option for NMIBC.
Advertisement
Related to this article
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Advertisement
Advertisement